Roxatidine: Difference between revisions

	WikiDoc Resources for Roxatidine
Articles
Most recent articles on Roxatidine Most cited articles on Roxatidine Review articles on Roxatidine Articles on Roxatidine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Roxatidine Images of Roxatidine Photos of Roxatidine Podcasts & MP3s on Roxatidine Videos on Roxatidine
Evidence Based Medicine
Cochrane Collaboration on Roxatidine Bandolier on Roxatidine TRIP on Roxatidine
Clinical Trials
Ongoing Trials on Roxatidine at Clinical Trials.gov Trial results on Roxatidine Clinical Trials on Roxatidine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Roxatidine NICE Guidance on Roxatidine NHS PRODIGY Guidance FDA on Roxatidine CDC on Roxatidine
Books
Books on Roxatidine
News
Roxatidine in the news Be alerted to news on Roxatidine News trends on Roxatidine
Commentary
Blogs on Roxatidine
Definitions
Definitions of Roxatidine
Patient Resources / Community
Patient resources on Roxatidine Discussion groups on Roxatidine Patient Handouts on Roxatidine Directions to Hospitals Treating Roxatidine Risk calculators and risk factors for Roxatidine
Healthcare Provider Resources
Symptoms of Roxatidine Causes & Risk Factors for Roxatidine Diagnostic studies for Roxatidine Treatment of Roxatidine
Continuing Medical Education (CME)
CME Programs on Roxatidine
International
Roxatidine en Espanol Roxatidine en Francais
Business
Roxatidine in the Marketplace Patents on Roxatidine
Experimental / Informatics
List of terms related to Roxatidine

Roxatidine acetate
Clinical data
Routes of; administration	Oral
ATC code	A02BA06 (WHO) ;
Pharmacokinetic data
Bioavailability	80–90%
Protein binding	5–7%
Metabolism	Hepatic deacetylation; Minor involvement of CYP2D6 and CYP2A6
Elimination half-life	5–7 hours
Excretion	Renal
Identifiers
	IUPAC name 2-oxo-2-(3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino)ethyl acetate;
CAS Number	78628-28-1 ;
PubChem CID	5105;
DrugBank	DB08806 ;
ChemSpider	4926 ;
UNII	IV9VHT3YUM;
KEGG	D08495 ;
ChEMBL	ChEMBL46102 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C19H28N2O4
Molar mass	348.437 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC(=O)NCCCOc1cc(ccc1)CN2CCCCC2)C;
	InChI InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23) ; Key:SMTZFNFIKUPEJC-UHFFFAOYSA-N ;
(what is this?) (verify)

← Older edit

VisualWikitext

Latest revision as of 13:55, 13 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Roxatidine acetate is a specific and competitive histamine H₂ receptor antagonist drug that is used to treat gastric ulcers, Zollinger–Ellison syndrome, erosive esophagitis, gastro-oesophageal reflux disease, and gastritis.^[1]^[2]

Pharmacodynamic studies showed that 150 mg of roxatidine acetate were optimal in suppressing gastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion.^[1]

It is available in countries including China, Japan, Korea, Germany, Italy, the Netherlands, Greece and South Africa.^[2]

References

↑ ^1.0 ^1.1 Murdoch D, McTavish D (1991). "Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders". Drugs. 42 (2): 240–260. doi:10.2165/00003495-199142020-00006. PMID 1717223.
↑ ^2.0 ^2.1 BioSpectrum Bureau 1 November 2012 Sinhuan's generic heart drug gets production approval

Template:H2-receptor antagonist

[Murdoch-1] 1.0 ^1.1 Murdoch D, McTavish D (1991). "Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders". Drugs. 42 (2): 240–260. doi:10.2165/00003495-199142020-00006. PMID 1717223.

[Biospectrum-2] 2.0 ^2.1 BioSpectrum Bureau 1 November 2012 Sinhuan's generic heart drug gets production approval

[1]

[2]

@@ Line 3: / Line 3: @@
 | verifiedrevid = 464384032
 | IUPAC_name = 2-oxo-2-(3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino)ethyl acetate
-| image = Roxatidine acetate.svg
+| image = Roxatidine.png
 | width = 250
 | drug_name = Roxatidine acetate
@@ Line 48: / Line 48: @@
 | StdInChIKey = SMTZFNFIKUPEJC-UHFFFAOYSA-N
 }}
+              __NOTOC__
+{{SI}}
+{{CMG}}
+==Overview==
 '''Roxatidine acetate''' is a specific and competitive [[H2 antagonist|histamine H<sub>2</sub> receptor antagonist]] drug that is used to treat [[gastric ulcers]], [[Zollinger–Ellison syndrome]],  [[erosive esophagitis]],  [[gastro-oesophageal reflux disease]], and [[gastritis]].<ref name=Murdoch>{{cite journal |title = Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders |author = Murdoch D, McTavish D |journal =Drugs |year = 1991 |volume = 42 |issue = 2 |pages = 240–260 |pmid = 1717223 |url = http://ukpmc.ac.uk/abstract/MED/1717223 |doi=10.2165/00003495-199142020-00006}}</ref><ref name=Biospectrum>BioSpectrum Bureau 1 November 2012  [http://www.biospectrumasia.com/biospectrum/news/121261/sinhua-heart-generic-production-approval Sinhuan's generic heart drug gets production approval]</ref>
@@ Line 57: / Line 63: @@
 {{reflist|2}}
-{{Histaminergics}}
 {{H2-receptor antagonist}}
@@ Line 63: / Line 69: @@
 [[Category:Piperidines]]
 [[Category:Phenol ethers]]
-[[Category:Acetamides]]
+[[Category:Drug]]
-[[Category:Acetate esters]]
-{{gastrointestinal-drug-stub}}

Clinical data

Routes of administration	Oral
ATC code	A02BA06 (WHO)
Pharmacokinetic data
Bioavailability	80–90%
Protein binding	5–7%
Metabolism	Hepatic deacetylation Minor involvement of CYP2D6 and CYP2A6
Elimination half-life	5–7 hours
Excretion	Renal
Identifiers
IUPAC name 2-oxo-2-(3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino)ethyl acetate
CAS Number	78628-28-1^N
PubChem CID	5105
DrugBank	DB08806^Y
ChemSpider	4926^Y
UNII	IV9VHT3YUM
KEGG	D08495^Y
ChEMBL	ChEMBL46102^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₉H₂₈N₂O₄
Molar mass	348.437 g/mol
3D model (JSmol)	Interactive image
SMILES O=C(OCC(=O)NCCCOc1cc(ccc1)CN2CCCCC2)C
InChI InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23)^Y Key:SMTZFNFIKUPEJC-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)

Roxatidine: Difference between revisions

Latest revision as of 13:55, 13 April 2015

Overview

References

Navigation menu

Search